Studies are ongoing in breast cancer to investigate the effect of anti-androgen treatment in patients with AR positive tumors with loss of ERα and PR (ClinicalTrials.gov Identifier NCT00468715, NCT01889238). This evidence concerns the gene AR and breast carcinoma.